"Immunotherapy, Active" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
| Descriptor ID |
D016233
|
| MeSH Number(s) |
E02.095.465.425.400.530 E05.478.550.600
|
| Concept/Terms |
Immunotherapy, Active- Immunotherapy, Active
- Active Immunotherapy
- Active Immunotherapies
- Immunotherapies, Active
Vaccine Therapy- Vaccine Therapy
- Therapy, Vaccine
- Therapies, Vaccine
- Vaccine Therapies
Immune RNA Manipulation- Immune RNA Manipulation
- Immune RNA Manipulations
- Manipulation, Immune RNA
- Manipulations, Immune RNA
- RNA Manipulation, Immune
- RNA Manipulations, Immune
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Active".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Active".
This graph shows the total number of publications written about "Immunotherapy, Active" by people in this website by year, and whether "Immunotherapy, Active" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 1 | 3 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Active" by people in Profiles.
-
Shore ND. PROSTVAC? targeted immunotherapy candidate for prostate cancer. Immunotherapy. 2014; 6(3):235-47.
-
Selvan SR, Carbonell DJ, Fowler AW, Beatty AR, Ravindranath MH, Dillman RO. Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res. 2010 Aug; 20(4):280-92.
-
Dillman R, Barth N, Selvan S, Beutel L, de Leon C, DePriest C, Peterson C, Nayak S. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm. 2004 Oct; 19(5):581-8.
-
Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002 Feb; 109(3):409-17.
-
Berd D, Kairys J, Dunton C, Mastrangelo MJ, Sato T, Maguire HC. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol. 1998 Dec; 25(6):646-53.
-
Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother. 1998 Sep; 47(1):1-12.
-
Mastrangelo MJ, Sato T, Lattime EC, Maguire HC, Berd D. Cellular vaccine therapies for cancer. Cancer Treat Res. 1998; 94:35-50.
-
Berd D, Maguire HC, Mastrangelo MJ, Murphy G. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol Immunother. 1994 Sep; 39(3):141-7.
-
Berd D, Maguire HC, Mastrangelo MJ. Treatment of human melanoma with a hapten-modified autologous vaccine. Ann N Y Acad Sci. 1993 Aug 12; 690:147-52.
-
Wiktor TJ, MacFarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, Wunner WH, Kieny MP, Lathe R, Lecocq JP, Mackett M, et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. 1984. Biotechnology. 1992; 24:508-12.